✦ LIBER ✦

Re: Gender Difference in Efficacy and Dose Response in Japanese Patients with Nocturia Treated with Four Different Doses of Desmopressin Orally Disintegrating Tablet in a Randomized, Placebo-Controlled Trial

✍ Scribed by Griebling, Tomas

Book ID: 122935249
Publisher: Lippincott Williams and Wilkins
Year: 2013
Tongue: English
Weight: 98 KB
Volume: 190
Category: Article
ISSN: 0022-5347
DOI: 10.1016/j.juro.2013.04.122

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Re: Efficacy and Safety of Low Dose Desm

Re: Efficacy and Safety of Low Dose Desmopressin Orally Disintegrating Tablet in Women with Nocturia: Results of a Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study

✍ Petros, Peter P. 📂 Article 📅 2014 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 48 KB

Efficacy and Safety of Low Dose Desmopre

Efficacy and Safety of Low Dose Desmopressin Orally Disintegrating Tablet in Men with Nocturia: Results of a Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study

✍ Weiss, Jeffrey P.; Herschorn, Sender; Albei, Cerasela D.; van der Meulen, Egbert 📂 Article 📅 2013 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 688 KB

Efficacy and Safety of Low Dose Desmopre

Efficacy and Safety of Low Dose Desmopressin Orally Disintegrating Tablet in Women with Nocturia: Results of a Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study

✍ Sand, Peter K.; Dmochowski, Roger R.; Reddy, Jyotsna; van der Meulen, Egbert A. 📂 Article 📅 2013 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 757 KB

Efficacy and safety of sublingual fentan

Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined by titration for the treatment of breakthrough pain in Japanese cancer patients: a multicenter, randomized, placebo-controlled, double-blind phase III trial

✍ Shimoyama, Naohito; Gomyo, Ikuo; Katakami, Nobuyuki; Okada, Masakuni; Yukitoshi, 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 282 KB

Efficacy and safety of four doses of lum

Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: A phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial

✍ Schnitzer, Thomas J. ;Beier, Jannie ;Geusens, Piet ;Hasler, Paul ;Patel, Sanjay 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB 👁 3 views

## Abstract ## Objective To compare the efficacy and tolerability of the novel cyclooxygenase 2‐selective inhibitor lumiracoxib with placebo and diclofenac in osteoarthritis (OA). ## Methods Adults (n = 583) with knee or hip OA were randomized to receive for 4 weeks lumiracoxib 50, 100, or 200 m

Febuxostat, a novel nonpurine selective

Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: A twenty-eight–day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout

✍ Michael A. Becker; H. Ralph Schumacher Jr.; Robert L. Wortmann; Patricia A. MacD 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 168 KB 👁 3 views

## Abstract ## Objective Gout affects ∼1–2% of the American population. Current options for treating hyperuricemia in chronic gout are limited. The purpose of this study was to assess the safety and efficacy of febuxostat, a nonpurine selective inhibitor of xanthine oxidase, in establishing normal